Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have signed and dated a consent form agreeing to take part in the study
- People aged 18 or older who have been diagnosed with Philadelphia chromosome-positive chronic myeloid leukaemia in the chronic phase (a specific type of blood cancer at an early stage)
- People whose blood and bone marrow test results fall within specific ranges — less than 15% blast cells, less than 30% blasts plus promyelocytes, less than 20% basophils, and a platelet count of at least 50,000 per mm³ (confirm with trial site if these terms are unfamiliar)
- People who have previously been treated with at least 2 different targeted therapy drugs known as TKIs, including imatinib, and at least one of dasatinib, nilotinib, bosutinib, or ponatinib
- People who are already receiving a drug called asciminib as part of their current treatment, in line with its approved use in their country, and who started asciminib no more than 6 months before joining the study
Who may not be able to join:
- People for whom asciminib was the first or second treatment tried for their condition
- People who are currently taking part in another clinical trial
- People who have declined to sign the informed consent form
- People who, in the treating doctor's judgement, are unlikely to be able to provide an accurate medical history or to be followed up over the long term — for example, due to serious other illnesses or availability concerns
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: +41613241111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Major molecular response (MMR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.